Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM
Status:
Terminated
Trial end date:
2023-01-09
Target enrollment:
Participant gender:
Summary
The primary purpose is to determine the safety and tolerability of belantamab mafodotin in
combination with other anti-cancer treatments (in each sub-study), and to establish the
recommended Phase 2 dose for each combination treatment to explore in the cohort expansion
phase. This study is the sub study of the Master protocol (NCT04126200).